Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Minimal Residual Disease Testing Market, by Application
1.4.2 North America Minimal Residual Disease Testing Market, by End User
1.4.3 North America Minimal Residual Disease Testing Market, by Technology
1.4.4 North America Minimal Residual Disease Testing Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Minimal Residual Disease Testing Market by Application
3.1 North America Hematological Malignancies Market by Country
3.2 North America Leukemia Market by Country
3.3 North America Lymphoma Market by Country
3.4 North America Solid Tumors Market by Country
3.5 North America Others Market by Country
Chapter 4. North America Minimal Residual Disease Testing Market by End User
4.1 North America Hospitals & Specialty Clinics Market by Country
4.2 North America Diagnostic Laboratories Market by Country
4.3 North America Academic & Research Institutes Market by Country
4.4 North America Others Market by Country
Chapter 5. North America Minimal Residual Disease Testing Market by Technology
5.1 North America Polymerase Chain Reaction (PCR) Market by Country
5.2 North America Next-Generation Sequencing (NGS) Market by Country
5.3 North America Flow Cytometry Market by Country
5.4 North America Others Market by Country
Chapter 6. North America Minimal Residual Disease Testing Market by Country
6.1 US Minimal Residual Disease Testing Market
6.1.1 US Minimal Residual Disease Testing Market by Application
6.1.2 US Minimal Residual Disease Testing Market by End User
6.1.3 US Minimal Residual Disease Testing Market by Technology
6.2 Canada Minimal Residual Disease Testing Market
6.2.1 Canada Minimal Residual Disease Testing Market by Application
6.2.2 Canada Minimal Residual Disease Testing Market by End User
6.2.3 Canada Minimal Residual Disease Testing Market by Technology
6.3 Mexico Minimal Residual Disease Testing Market
6.3.1 Mexico Minimal Residual Disease Testing Market by Application
6.3.2 Mexico Minimal Residual Disease Testing Market by End User
6.3.3 Mexico Minimal Residual Disease Testing Market by Technology
6.4 Rest of North America Minimal Residual Disease Testing Market
6.4.1 Rest of North America Minimal Residual Disease Testing Market by Application
6.4.2 Rest of North America Minimal Residual Disease Testing Market by End User
6.4.3 Rest of North America Minimal Residual Disease Testing Market by Technology
Chapter 7. Company Profiles
7.1 Bio-Rad Laboratories, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Guardant Health, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Product Launches and Product Expansions:
7.3 Invitae Corporation (ArcherDX, Inc.)
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 Bio-Techne Corporation
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expenses
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Approvals & Trails:
7.6 ICON plc (MolecularMD Corporation)
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 Natera Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expenses
7.8 Sysmex Corporation
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.9 Laboratory Corporation of America Holdings
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental Analysis
7.9.4 Recent strategies and developments:
7.9.4.1 Partnerships, Collaborations, and Agreements:
7.9.4.2 Product Launches and Product Expansions:
7.10. Invivoscribe, Inc.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Partnerships, Collaborations, and Agreements: